PHI with Refractory celiac disease
How does this condition affect your private health insurance?
Refractory Celiac Disease (RCD) is a rare and severe form of celiac disease where the small intestine does not heal despite strict adherence to a gluten-free diet for at least 6-12 months. It's characterized by persistent symptoms like chronic diarrhea, malabsorption, and weight loss. RCD is classified into Type I and Type II; Type II has a poorer prognosis and a significant risk of developing enteropathy-associated T-cell lymphoma (EATL). Diagnosis involves biopsy and immunophenotyping. Treatment options are limited and often involve immunosuppressants.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Persistent, often several months to years before diagnosis of refractoriness.
Duration of Illness (Lifetime)
Chronic, lifelong condition requiring continuous management.
Cost of Treatment (Initial)
Moderate to high (diagnostic procedures, initial medication, specialist consultations).
Cost of Treatment (Lifetime)
High (ongoing medication, regular follow-ups, potential for complications and hospitalizations, specialized diet).
Mortality Rate
Moderate to high, particularly for Type II Refractory Celiac Disease due to increased risk of complications like enteropathy-associated T-cell lymphoma.
Risk of Secondary Damages
High (severe malabsorption, malnutrition, osteoporosis, anemia, increased risk of enteropathy-associated T-cell lymphoma, neurological issues).
Probability of Full Recovery
Low (complete histological and clinical recovery is rare, especially for Type II; the disease often requires ongoing management).
Underlying Disease Risk
Moderate (celiac disease itself is associated with other autoimmune conditions like Type 1 diabetes or autoimmune thyroid disease; the main 'underlying' risk for RCD is progression to lymphoma).